2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

Documenti analoghi

• 12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
  di: Kümmerle-Deschner J, et al.
  Pubblicazione: (2008-09-01)
• Additional Benefit of Canakinumab on Proteinuria in a Case With Muckle-Wells Syndrome in Remission Under Anakinra
  di: Ufuk İLGEN, et al.
  Pubblicazione: (2020-03-01)
• 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
  di: Ruperto N, et al.
  Pubblicazione: (2008-09-01)
• Delayed diagnosis of Muckle-Wells syndrome – analysis of influencing factors
  di: Kuemmerle-Deschner Jasmin B, et al.
  Pubblicazione: (2012-07-01)
• Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
  di: Angel Luis Salcedo-Mingoarranz, et al.
  Pubblicazione: (2023-12-01)